La cadena de opciones muestra datos clave de las opciones de acciones de Anixa Biosciences a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Anixa Biosciences..

Anixa Biosciences (NASDAQ:ANIX) Bolsa, Cadena de Opciones

Anixa Biosciences

Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Anixa Biosciences Inc

Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) CEO Mark Zuckerberg revealed during the company&#8217;s <a href="https://www.benzinga.com/news/earnings/24/10/41637326/meta-platforms-q3-earnings-revenue-beat-eps-beat-daily-actives-up-5-strong-momentum-in-ai">third quarter 2024 earnings call</a> that Meta is developing its next-generation AI model, Llama 4, using what he described as an unprecedented computing infrastructure of more than 100,000 NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) H100 GPUs.
What Happened: &#8220;We&#8217;re training the Llama 4 models on a cluster that is bigger than 100,000 H100s or bigger than anything that I&#8217;ve seen reported for what others are doing,&#8221; Zuckerberg said during the earnings call. 
The new models are expected to be ready in early 2025, with smaller versions launching first.
Zuckerberg also highlighted how Meta&#8217;s open-source approach to Llama is yielding benefits through chip optimization from major semiconductor manufacturers. &#8220;What we&#8217;re seeing is that as Llama gets adopted more, you&#8217;re seeing folks like NVIDIA and Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) optimize their chips more to run Llama specifically well, which clearly benefits us,&#8221; he explained.
The Meta CEO drew parallels to the company&#8217;s previous success with its Open Compute Project, noting that sharing technological designs led to industry standardization and cost savings. This strategy appears to be repeating with Llama, as chip manufacturers optimize their hardware specifically for the AI model.
The upcoming Llama 4 is expected to feature significant improvements over its predecessor, with Zuckerberg indicating it will be &#8220;a big deal on several fronts, new modalities, capabilities, stronger reasoning, and much faster.&#8221;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41638933/riot-platforms-stock-falls-after-worse-than-expected-q3-results">Riot Platforms Stock Falls After Worse-Than-Expected Q3 Results</a>
Why It Matters: The development of Llama 4 is a significant step for Meta Platforms, especially given the company&#8217;s recent strong financial performance. Meta Platforms reported third-quarter revenue of $40.59 billion, beating <a href="https://www.benzinga.com/news/earnings/24/10/41637326/meta-platforms-q3-earnings-revenue-beat-eps-beat-daily-actives-up-5-strong-momentum-in-ai">analyst estimates</a> of $40.29 billion. The company also reported third-quarter adjusted earnings of $6.03 per share, surpassing analyst estimates of $5.25 per share.
Despite this, Meta Platforms has faced some internal challenges, including the recent firing of approximately two dozen employees, including one earning $400,000 per year, for <a href="https://www.benzinga.com/startups/24/10/41565180/a-400kyear-meta-employee-fired-for-violating-meal-credit-policy-bought-tea-and-toothpaste-calls-it-a">violating the company&#8217;s meal credit rules</a>.
Price Action: Meta stock closed at $591.80, down 0.25% on Wednesday. In after-hours trading, the stock declined further, dropping 3.18%. Year to date, Meta has shown substantial growth, surging by 70.90%, according to <a href="https://pro.benzinga.com/dashboard">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41636770/microsoft-q1-earnings-highlights-ai-driven-transformation-is-changing-work-company-beats-revenue-ep">Microsoft Q1 Earnings Highlights: &#8216;AI-Driven Transformation Is Changing Work,&#8217; Company Beats Revenue, EPS Estimates</a></li>
</ul>
Image Via Shutterstock 
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

News

Markets

Tech

NVDA

Mark Zuckerberg Says Meta's Open-Source Gambit Is Paying Off As Nvidia And AMD Optimize For Llama: 'A Big Deal On Several Fronts'

U.S. stock indices closed lower on Wednesday, as the Dow Jones Industrial Average slipped 0.2% to 42,141.54, while the S&amp;P 500 edged down 0.3% to 5,813.67. The Nasdaq saw a steeper decline, falling nearly 0.6% to 18,607.93.
The U.S. economy <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41623984/us-economy-grows-less-than-expected-in-q3-yet-private-employment-soars-by-233-000">expanded by 2.8% in the third quarter</a>, missing expectations of 3% growth, while the ADP report showed a strong October increase in private payrolls with 233,000 jobs added, well above forecasts. 
These are the top stocks that gained the attention of retail traders and investors throughout the day:
Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) closed the day with a slight decrease of 0.25% at $591.8. The stock hit an intraday high of $601.2 and a low of $589.38. Its 52-week range is $296.86 to $602.95. Meta reported <a href="https://www.benzinga.com/news/earnings/24/10/41637326/meta-platforms-q3-earnings-revenue-beat-eps-beat-daily-actives-up-5-strong-momentum-in-ai">third-quarter revenue</a> of $40.59 billion, surpassing analyst estimates of $40.29 billion. The company also reported adjusted earnings of $6.03 per share, beating analyst estimates of $5.25 per share. 
Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) saw a marginal increase of 0.13%, closing at $432.53. The stock&#8217;s intraday high and low were $438.5 and $432.1, respectively, with a 52-week range between $334.69 and $468.35. Microsoft reported a first-quarter revenue of $65.60 billion, <a href="https://www.benzinga.com/news/earnings/24/10/41636770/microsoft-q1-earnings-highlights-ai-driven-transformation-is-changing-work-company-beats-revenue-ep">up 16% year-over-year,</a> beating the Street consensus estimate of $64.51 billion.
See Also: <a href="https://www.benzinga.com/general/entertainment/24/10/41616337/google-bought-youtube-for-1-65b-and-now-it-prints-50b-in-revenue-just-in-1-year-sundar-pich?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Google Bought YouTube For $1.65B And Now It Prints $50B In Revenue Just In 1 Year — Sundar Pichai Says Alphabet &#8216;Leaning Into The Living Room Experience&#8217;</a>
Robinhood Markets Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) ended the day with a 0.64% increase at $28.21. The stock reached an intraday high of $28.58 and a low of $27.55. Its 52-week range is $7.91 to $28.58. Robinhood reported <a href="https://www.benzinga.com/news/earnings/24/10/41636963/robinhood-stock-drops-after-q3-revenue-miss-details">quarterly earnings</a> of 17 cents per share, meeting the analyst consensus estimate. However, its quarterly revenue of $637 million missed the analyst consensus estimate of $650.67 million. 
Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) plunged 32.68% to close at $33.07. The stock&#8217;s intraday high was $38, and it hit a low of $32.2. Its 52-week range is $22.66 to $122.9. Super Micro Computer's shares plunged after its auditor, Ernst &amp; Young, resigned, citing <a href="https://www.benzinga.com/trading-ideas/movers/24/10/41625460/super-micro-computer-stock-dives-as-auditor-resigns-whats-going-on">governance, transparency, and ethical concerns</a>. In response, Super Micro's board appointed a special committee to investigate the issues raised.
Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) closed down 3.61% at $211.74. The stock&#8217;s intraday high and low were $220.46 and $209.47, respectively, with a 52-week range of $73.56 to $283.48. The cryptocurrency exchange that allows users to trade in digital assets like Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) reported <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41637702/coinbase-q3-earnings-highlights-revenue-miss-eps-miss-transaction-revenue-falls-from-q2">third-quarter revenue</a> of $1.21 billion, missing the Street consensus estimate of $1.26 billion. 
Image via Shutterstock
Prepare for the day&#8217;s trading <a href="Premarket Movers &amp; News">with top premarket movers and news</a> by Benzinga.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41568577/elon-musk-channels-warren-buffett-as-teslas-stock-booms-after-strong-q3-having-a-publicly-traded?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Channels Warren Buffett As Tesla&#8217;s Stock Booms After Strong Q3: &#8216;Having A Publicly Traded Company Is Like…&#8217;</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

$BTC

$ETH

COIN

HOOD

MSFT

SMCI

Meta, Microsoft, Robinhood, Super Micro, And Coinbase: Why These 5 Stocks Are On Investors' Radars Today

MariMed Inc. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MRMD#OTC">MRMD</a>), a prominent multi-state cannabis operator is doubling down on its growth strategy by launching manufacturing operations in Missouri while expanding capacity in Illinois. 
With Missouri marking its sixth state of operation, MariMed aims to extend its <a href="https://www.benzinga.com/topic/edibles">branded product range</a>, including Betty's Eddies fruit chews and Bubby's Baked confections, across the state by late November, tapping into Missouri's burgeoning market just in time for the holidays.
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. You can&#8217;t afford to miss out if you're serious about the business.</li>
</ul>
<h3 class="wp-block-heading">Missouri's Fast-Growing Market</h3>
MariMed's chief revenue officer Ryan Crandall <a href="https://www.globenewswire.com/en/news-release/2024/10/30/2971587/0/en/MariMed-Commences-Manufacturing-Operations-in-Missouri.html">expressed optimism</a> about the Missouri expansion. "Expanding our branded products into Missouri has been a key goal for us.<a href="https://www.benzinga.com/topic/missouri-cannabis"> Missouri's fast-growing market </a>is eager for high-quality products." 
Until regulatory approval for license transfer is granted, MariMed will operate the Missouri facility under a Managed Services Agreement (MSA).
<h3 class="wp-block-heading">Strategic Growth In Illinois: A $496 Million Market</h3>
MariMed&#8217;s expansion in Illinois is critical to its growth, as the state accounted for 40-45% of the company's sales in Q3, amid a $496 million cannabis market driven primarily by recreational sales.&nbsp;
Analyst<a href="https://www.benzinga.com/topic/pablo-zuanic"> Pablo Zuanic</a> from Zuanic &amp; Associates <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41536686/can-marimeds-7-7m-illinois-cannabis-expansion-turn-the-tide-in-a-496m-market">emphasizes the significance of Illinois</a>, despite challenges like declining per capita spending ($160) and reduced per-store revenue, which dropped to $8.8 million annually.&nbsp;
To capture more market share, MariMed is investing $7.7 million in a new 14,000-square-foot cultivation site, expected to start sales by early 2025, capitalizing on Illinois' high wholesale prices and increasing its production capabilities.
Read Also:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41561831/m-a-frenzy-and-deflation-post-election-which-companies-are-ready-to-win-big-in-flor"> M&amp;A Frenzy And Deflation Post-Election: Which Companies Are Ready To Win Big In Florida&#8217;s Cannabis Market</a>
<h3 class="wp-block-heading">Mixed Results Across State Markets</h3>
In other states, MariMed's performance varies with market dynamics. <a href="https://www.benzinga.com/topic/maryland-cannabis">Maryland's mature cannabis market </a>yielded $292 million in Q3 sales, an 8% increase year-over-year.&nbsp;
Meanwhile, <a href="https://www.benzinga.com/topic/massachusetts-cannabis">Massachusetts </a>faced price deflation, leading to a 17% drop in branded sales.&nbsp;
Read Next:<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41613366/beyond-beer-tilrays-1-67-billion-market-play-is-this-cannabis-giant-still-a-smart-b"> Beyond Beer, Tilray&#8217;s $1.67 Billion Market Play: Is This Cannabis Giant Still A Smart Buy?</a>

Cannabis

Market Summary

Financing

Contracts

Retail Sales

Management

Real Estate

MRMD

Edibles Surge In The Heartland: MariMed's Play For Missouri And Illinois Cannabis Dominance

The cryptocurrency market frenzy paused Tuesday as Bitcoin remained rangebound below its all-time high.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Gains +/-</td>
<td>Price (Recorded at 8:45 p.m. EDT)</td>
</tr>
<tr>
<td>Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)</td>
<td>-0.27%</td>
<td>$72,106.26</td>
</tr>
<tr>
<td>Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>+1.32%</td>
<td>$2,656.70</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
<td>-3.54%</td>
<td>$0.1683</td>
</tr>
</tbody>
</table>
</figure>
What Happened: The world's largest cryptocurrency almost set a new all-time high Monday before traders started to take profits.
On Tuesday, Bitcoin was glued in the $72,000 region, hitting an intraday high of $72,905 early in the evening.
Ethereum reversed course after breaking $2,700 briefly in the early morning hours.
Total cryptocurrency liquidations exceeded $100 million over the last 24 hours, with $62 million in bullish leveraged bets getting wiped out.
Bitcoin's Open Interest rose 0.20% in the last 24 hours, in line with the sideways movement of the spot price.
Additionally, more than 61% of all derivatives traders with open positions were short on Bitcoin, according to the Long/Short Ratio.
"Extreme Greed" engulfed the market, as per the Cryptocurrency Fear and Greed Index, raising fears of a potential correction.
Top Gainers (24-Hours)
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Gains +/-</td>
<td>Price (Recorded at 8:45 p.m. EDT)</td>
</tr>
<tr>
<td>Maker (MKR)</td>
<td>+8.45%</td>
<td>$1,245.43</td>
</tr>
<tr>
<td>Chainlink (LINK)</td>
<td>+5.24%</td>
<td>$12.37</td>
</tr>
<tr>
<td>Aave (AAVE)</td>
<td>+4.53%</td>
<td>$156.93</td>
</tr>
</tbody>
</table>
</figure>
The global cryptocurrency stood at $2.42 trillion, following a contraction of 0.15% in the last 24 hours.
Stocks pulled back from Tuesday&#8217;s highs. The Dow Jones Industrial Average slipped 91.51 points, or 0.22%, to end at 42,141.54. The S&amp;P 500 fell 0.33% to close at 5,813.67, while the tech-focused Nasdaq Composite tumbled 0.56% from its record close from the previous day, ending at 18,607.93.
Investors parsed <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41623984/us-economy-grows-less-than-expected-in-q3-yet-private-employment-soars-by-233-000">key macroeconomic data</a>, including slower-than-expected U.S. GDP growth in the third quarter and higher-than-expected private employment growth in October.
The market has priced in a more than 95% possibility of the Federal Reserve cutting interest rates by 0.25% at its FOMC meeting next week, <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">according </a>to CME FedWatch tool.
See More: <a href="https://www.benzinga.com/money/best-crypto-scanners">Best Cryptocurrency Scanners</a>
Analyst Notes: Popular cryptocurrency analyst Michaël van de Poppe noted that Bitcoin was approaching its new all-time high faster than what he previously predicted.
"I think $80,000 in November, $90,000-100,000 in December, and altcoins to strongly outperform as yields are going to drop," the analyst issued a fresh projection.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">It was less than 2-4 weeks and we&#39;ve got close to the all-time high for <a href="https://twitter.com/hashtag/Bitcoin?src=hash&amp;ref_src=twsrc%5Etfw">#Bitcoin</a>. What&#39;s next? I think $80,000 in November, $90,000-100,000 in December and <a href="https://twitter.com/hashtag/Altcoins?src=hash&amp;ref_src=twsrc%5Etfw">#Altcoins</a> to strongly outperform as Yields are going to drop. <a href="https://t.co/tsPmdZJwAl">https://t.co/tsPmdZJwAl</a>
&mdash; Michaël van de Poppe (@CryptoMichNL) <a href="https://twitter.com/CryptoMichNL/status/1851640217402499145?ref_src=twsrc%5Etfw">October 30, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Similarly, he predicted Ethereum to top the $3,000 level in November.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Ethereum?src=hash&amp;ref_src=twsrc%5Etfw">#Ethereum</a> took the liquidity and ran back up to resistance. I think we&#39;ll break through it in the next 1-2 weeks and see $3,000+ in November. <a href="https://t.co/m96p7YyXuC">pic.twitter.com/m96p7YyXuC</a>
&mdash; Michaël van de Poppe (@CryptoMichNL) <a href="https://twitter.com/CryptoMichNL/status/1851617552788845028?ref_src=twsrc%5Etfw">October 30, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
J.A. Maartunn, author at on-chain analytics firm CryptoQuant, drew attention to the growing retail investor demand for Bitcoin, which hit its highest level in seven months.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">&#x1f631; Retail Investor Demand Hits Highest Level in 7 Months <a href="https://t.co/BLF83Kctrr">pic.twitter.com/BLF83Kctrr</a>
&mdash; Maartunn (@JA_Maartun) <a href="https://twitter.com/JA_Maartun/status/1851709487423401986?ref_src=twsrc%5Etfw">October 30, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Read Next:&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41635149/2024-election-odds-on-polymarket-kalshi-show-trump-will-win-why-they-might-be-wrong">2024 Election Odds On Polymarket, Kalshi Show Trump Will Win: Why They Might Be Wrong</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

Trading Ideas

$DOGE

Bitcoin, Dogecoin Cool Down, Ethereum Gains As Stocks Reverse On Q3 GDP Numbers: Analyst Predicts BTC At $80K In November, $90K-100K By December

Tesla&#8217;s futuristic <a href="https://www.benzinga.com/topic/cybertruck">Cybertruck</a> has been a hot topic since its release. It is known for its bold design and promises of robust performance, but now that it&#8217;s on the road, not every owner gets the smooth ride they expected.&nbsp;
One frustrated owner took matters into his own hands when Tesla&#8217;s service team couldn&#8217;t fix a persistent issue with his vehicle. Here's how he did it with a $12 part.
Don't Miss:
<ul>
<li>This Adobe-backed AI marketing startup went from a $5 to $85 million valuation working with brands like L'Oréal, Hasbro, and Sweetgreen in just three years –<a href="https://www.benzinga.com/money/rad-ai"> here's how there's an opportunity to invest at $1,000 for only $0.50/share today.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target –<a href="https://www.benzinga.com/money/mode-mobile-2"> You can still get 4,000 of its pre-IPO shares for just $1,000</a></li>
</ul>
<h2 class="wp-block-heading">A Whistle That Wouldn't Quit</h2>
When this Cybertruck owner first received his vehicle, the cabin was impressively quiet. Unfortunately, a factory defect in the windshield forced him to replace it and the problems began. After the windshield replacement, a high-pitched whistle started making highway drives unbearable. The noise – a piercing whistle at higher speeds – wasn't just annoying; it turned a futuristic truck into an unpleasant ride.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Anyone else have a high pitching wind noise in their Cybertruck?? Tesla service center in Tempe AZ said it was normal but I didn't have the noise before they replaced my windshield so after 2 trips to the service center with no improvement I fixed it myself. <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a> <a href="https://twitter.com/Tesla?ref_src=twsrc%5Etfw">@Tesla</a>… <a href="https://t.co/1rMnoFXRqT">pic.twitter.com/1rMnoFXRqT</a>
&mdash; MyCybertruckLife (@jaylarsondpm) <a href="https://twitter.com/jaylarsondpm/status/1849588230762451384?ref_src=twsrc%5Etfw">October 24, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h2 class="wp-block-heading">Tesla&#8217;s Service Troubles</h2>
The owner, hoping for a quick fix, brought his truck back to Tesla – twice. The first time, Tesla technicians assured him they had addressed the issue, but the whistle persisted. The second time, they told him the noise was &#8220;normal&#8221; for a Cybertruck. But the owner knew better – his Cybertruck had been perfectly quiet before replacing the windshield. Despite his insistence, Tesla couldn't reproduce the problem at highway speeds and refused to do anything further.
See Also: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O&#8217;Reilly and Rudy Giuliani are using this platform to <a href="https://www.benzinga.com/money/american-hartford-gold">create customized gold IRAs to help shield their savings from inflation and economic turbulence.&nbsp;</a>
This story echoes broader frustrations voiced by other Tesla owners. For example, a former Tesla owner recently shared how her repeated service visits and unresolved issues led her to sell her car entirely.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">One of the biggest reasons why I got rid of the Tesla is because it was always in service. It would take forever, and then, I would get stinky Uber credits. Aaaaand they would mess up something else or ignore one of the requests and I would need to go back again. Just had Rivian… <a href="https://t.co/enU1oJ1UZe">pic.twitter.com/enU1oJ1UZe</a>
&mdash; Jennifer Parker (@jenzfc) <a href="https://twitter.com/jenzfc/status/1796169825427026418?ref_src=twsrc%5Etfw">May 30, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Another owner also detailed his challenges with Tesla service after his Cybertruck failed to stop for a deer, leading to extensive damage and a long wait just to get an insurance estimate.&nbsp;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Hit the deer with my Tesla. FSD didn't stopped, even after hitting the deer on full speed. Huge surprise after getting a dozen of false stops every day! Experiencing worst side of Tesla service now. Can't even get an estimate for insurance. Nearest appointments only in January. <a href="https://t.co/7PMiROmk5x">pic.twitter.com/7PMiROmk5x</a>
&mdash; Paul S (@TheSeekerOf42) <a href="https://twitter.com/TheSeekerOf42/status/1850747727224987865?ref_src=twsrc%5Etfw">October 28, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h2 class="wp-block-heading">A Simple DIY Solution</h2>
Frustrated but determined, the Cybertruck owner decided to take matters into his own hands. After doing some research, he found an inexpensive solution: 9mm weather stripping that cost just $12. The weather stripping fit perfectly into the gap along the top of the windshield – no adhesive required. The result? The high-pitched whistle was gone and the cabin returned to its original quiet state, even at speeds over 90 mph.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
The fix was effective and easy to implement, requiring only the weather strip to be pressed into place. The owner was thrilled: &#8220;Looks perfect … But sounds even better. I love the sound of silence! even at 90+ mph!!!&#8221;
<h2 class="wp-block-heading">Tesla&#8217;s Persistent Service Problems</h2>
This isn&#8217;t an isolated case. Tesla owners have been experiencing increasing frustration with the brand&#8217;s service. From legal issues preventing Tesla employees from <a href="https://www.benzinga.com/markets/equities/24/10/41566293/tesla-cybertruck-customers-must-diy-off-road-light-bar-installation-as-employees-are-by-law-barr">installing accessories like the off-road light bar</a> for the &#8220;Cyberbeast&#8221; version of the truck, to widespread quality control challenges and <a href="https://www.benzinga.com/startups/24/09/40750931/cybertrucks-are-a-disaster-now-but-winter-will-be-a-nightmare-heres-why-cybertruck-owners-should-be">cold-weather performance issues</a>, many are questioning whether the Cybertruck – and Tesla&#8217;s service infrastructure – was truly ready for the market.
Despite the issues, the Cybertruck remains popular. Last quarter, it became the <a href="https://www.benzinga.com/news/24/10/41353805/elon-musks-tesla-dominates-us-ev-market-with-3-of-top-5-best-selling-models-in-q3">third bestselling EV in the U.S.</a>, behind only Tesla&#8217;s Model 3 and Model Y. However, as more owners face these problems, the enthusiasm around the Cybertruck may be tested.
Read Next:
<ul>
<li>‘Scrolling to UBI': Deloitte's #1 fastest-growing software company allows users to earn money on their phones –<a href="https://www.benzinga.com/money/mode-mobile-2"> invest today with $1,000 for just $0.25/share</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

Startups

Frustrated By Tesla's Inability To Repair His Cybertruck, Man Used A $12 Part. Here's How He Solved The Issue

Microsoft Corp.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) artificial intelligence momentum is expected to drive significant growth in the coming years, as highlighted by Wedbush Securities analyst Dan Ives. Following Microsoft's <a href="https://www.benzinga.com/news/earnings/24/10/41636770/microsoft-q1-earnings-highlights-ai-driven-transformation-is-changing-work-company-beats-revenue-ep">first-quarter earnings report</a> on Wednesday, Ives shared his bullish outlook, underscoring the tech giant's role in the unfolding AI revolution.
What Happened: In an appearance on CNBC's Overtime, Ives stated, "This is a company firing on all cylinders. We sit here 6-9 months from now, this is a $4 trillion market cap." 
Microsoft reported first-quarter revenue of $65.6 billion, marking a 16% increase year-over-year and surpassing the consensus estimate of $64.51 billion, according to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Earnings per share reached $3.30, exceeding expectations of $3.09. The company's operating income also rose to $65.6 billion, up 14% from last year, showcasing robust performance amid <a href="https://www.benzinga.com/news/earnings/24/10/41636770/microsoft-q1-earnings-highlights-ai-driven-transformation-is-changing-work-company-beats-revenue-ep">expanding AI-driven initiatives</a>.
Ives highlighted the enthusiasm around Microsoft's Intelligent Cloud segment, suggesting a bright outlook as AI continues to bolster revenue streams. "This is a growth acceleration story," Ives noted on X (formerly Twitter), further asserting that "cloud will drive growth looking ahead."
He added, "It is still the first, second inning of this AI revolution." Ives's comments reflect his belief that Microsoft&#8217;s AI and cloud initiatives will position the company for long-term growth, potentially propelling it toward a historic valuation.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The AI story looks robust at Microsoft and cloud will drive growth looking ahead <a href="https://twitter.com/CNBCOvertime?ref_src=twsrc%5Etfw">@CNBCOvertime</a> &#x1f3c6;&#x1f37f;&#x1f4fa;&#x1f402; <a href="https://t.co/utWlZyg0av">https://t.co/utWlZyg0av</a>
&mdash; Dan Ives (@DivesTech) <a href="https://twitter.com/DivesTech/status/1851778892312555601?ref_src=twsrc%5Etfw">October 31, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/news/earnings/24/10/41637326/meta-platforms-q3-earnings-revenue-beat-eps-beat-daily-actives-up-5-strong-momentum-in-ai">Meta Platforms Q3 Earnings: Revenue Beat, EPS Beat, Daily Actives Up 5%, &#8216;Strong Momentum&#8217; In AI</a>
Why It Matters: Microsoft&#8217;s strong performance in the AI sector is consistent with recent trends. The company&#8217;s aggressive push into AI infrastructure has been <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41597402/microsofts-ai-push-gains-ground-as-trends-are-visible-partners-see-a-revolution">well-supported by demand</a>, with 59% of its partners seeing its CapEx investments as such, according to a survey by JPMorgan.
However, Microsoft has also faced challenges in the AI space, such as <a href="https://www.benzinga.com/markets/equities/24/10/41592650/microsoft-accuses-google-of-astroturf-campaigns-targeting-its-cloud-business-says-search-giant-r">alleged covert lobbying campaigns</a> by Google to undermine its cloud computing business. 
Meanwhile, Microsoft&#8217;s potential Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) investment has also been a topic of interest, with MicroStrategy&#8216;s Michael Saylor humorously reaching out to Microsoft CEO Satya Nadella to offer his assistance in creating the <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41553322/michael-saylors-proposal-to-microsoft-ceo-satya-nadella-if-you-want-to-make-the-next-trill">next trillion-dollar opportunity</a>.
Price Action: Microsoft Corp's stock closed at $432.53 on Wednesday, up 0.13% for the day. In after-hours trading, the stock declined by 3.71%. Year-to-date, Microsoft shares have seen a notable gain of 16.63%, according to <a href="https://www.benzinga.com/pro/">data from Benzinga Pro</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41619022/trumps-billionaire-ally-plans-to-join-elon-musks-doge-if-named-treasury-secretary-recommen?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Trump&#8217;s Billionaire Ally Plans To Join Elon Musk&#8217;s DOGE If Named Treasury Secretary, Recommends Elimination Of These Subsidies</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Microsoft's AI Momentum Could Propel $4 Trillion Market Cap In 6-9 Months Amid 'Robust' Q1 Earnings, Says Dan Ives: 'This Is a Company Firing on All Cylinders'

On Wednesday, Cathie Wood-led Ark Invest made some significant trades, with the most notable ones involving Tesla Inc (TSLA), Advanced Micro Devices Inc (AMD), and Palantir Technologies Inc (PLTR).
The Tesla Trade: Ark Invest&#8217;s ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) and ARK Next Generation Internet ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKW#NYSE">ARKW</a>) sold a total of 62,151 shares of Tesla. Based on Tesla's closing price of $257.55 on Wednesday, the value of this trade is approximately $16 million. 
This move followed <a href="https://www.benzinga.com/markets/equities/24/10/41615718/cathie-woods-sky-high-vision-dumps-shares-of-cybercab-touting-tesla-for-this-evtol-play">Ark&#8217;s recent decision</a> to buy a substantial amount of Archer Aviation Inc (ACHR) shares on both Tuesday and Wednesday while selling shares of the Elon Musk-led company.
ARK Investment Management projects that Tesla&#8217;s driverless ride-hailing service could tap into an <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41593922/cathie-woods-ark-invest-sees-tesla-unlocking-11-trillion-revenue-potential-with-rob">$11 trillion revenue market</a>, leveraging low operating costs to undercut current ride-hail prices. Tesla aims to launch this service next year in Texas and California, initially with drivers, and targets fully autonomous rides pending regulatory approval. Even so, the Wood-led firm has been on a Tesla share-selling spree lately.
The AMD Trade: Ark Invest bought a total of 111,080 shares of Advanced Micro Devices across its ARKK, ARKW, ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) and ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>). This move comes in the wake of AMD&#8217;s <a href="https://www.benzinga.com/news/earnings/24/10/41612007/amd-q3-earnings-revenue-beat-eps-in-line-data-center-up-122-significant-growth-opportunities-ahead-">impressive Q3 earnings report</a>, which revealed a year-over-year revenue increase of 18%. The value of this trade, based on AMD&#8217;s closing price of $148.6 on Wednesday, is approximately $16.5 million.
The Palantir Trade: Ark Invest sold a total of 372,730 shares of Palantir Technologies across its ARKK, ARKQ, ARKW, and ARKX ETFs. Despite Palantir&#8217;s <a href="https://www.benzinga.com/news/24/10/41554264/palantir-technologies-stock-reaches-new-52-week-high-whats-going-on">recent 52-week high</a> and a strategic partnership with L3Harris Technologies Inc (LHX), Ark decided to reduce its stake. The value of this trade, based on Palantir&#8217;s closing price of $43.69 on Wednesday, is approximately $16.3 million.
See Also: <a href="https://www.benzinga.com/markets/equities/24/10/41568577/elon-musk-channels-warren-buffett-as-teslas-stock-booms-after-strong-q3-having-a-publicly-traded?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Channels Warren Buffett As Tesla&#8217;s Stock Booms After Strong Q3: &#8216;Having A Publicly Traded Company Is Like…&#8217;</a> 
Other Key Trades:
<ul>
<li>Cathie Wood Purchased 689365 shares of Archer Aviation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) through its ARKK ETF. This transaction was valued at $2.3 million.</li>
<li>The firm bought 3426 shares of Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), worth $2.03 million, through its ARKK and ARKW ETFs.</li>
<li>Ark Invest bought shares of Absci Corp (ABSI) and shares of Cerus Corp (CERS) through its ARKG ETF. </li>
</ul>
Image via Benzinga YouTube and Unsplash
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41616239/shytoshi-kusama-touts-shiba-inu-lifetime-gains-of-33774726-we-still-have-far-to-go-and-muc?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Shytoshi Kusama Touts Shiba Inu Lifetime Gains Of 33774726%: &#8216;We Still Have Far To Go And Much Work To Be Done&#8217;</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

ETFs

ACHR

ARKK

ARKQ

ARKW

ARKX

PLTR

TSLA

Cathie Wood Shuffles Her Tech Deck: Continues Dumping Tesla And Palantir, Stocks Up On AMD And Meta

At the recent <a href="https://www.benzinga.com/events/" target="_blank" rel="noreferrer noopener">Benzinga Cannabis Capital Conference</a>, industry leaders explored the intersection of medical cannabis access, patient loyalty and market challenges.
Addressing key issues such as regulatory hurdles, changes in the medical marijuana market and the importance of patient education, the panel provided insights into maintaining patient care and access in a competitive market.
<h3 class="wp-block-heading">Navigating Accessibility And Risks To Medical Marijuana</h3>
Dr. Christina Betancourt Johnson, CEO of The Forest by Standard Wellness Maryland, highlighted the challenges in preserving patient access amid the rise of adult-use cannabis. Her <a href="https://www.benzinga.com/markets/cannabis/23/10/35098103/setting-the-gold-standard-premium-everyday-cannabis-with-standard-wellness">company</a>, which also operates in states like Utah, Missouri and Ohio, emphasizes the need for active engagement with elected officials and regulators to advocate for patients, especially when transitions between medical and adult use take place.
"We build those relationships long before coming into the market," she said. To her, lawmakers aren&#8217;t normally familiar with cannabis, so education is of the essence. In those conversations, Johnson advocates for tax breaks for medical users, mandatory shelf space dedicated to patients and enhanced budtender education to prioritize quality care as states transition to adult-use markets.
<h3 class="wp-block-heading">The ‘Friction' Between Medical And Adult-Use Markets</h3>
Founder of Leafwell, Emily Fisher, noted that the adult-use market introduces a type of "friction" that complicates access for patients. <a href="https://www.benzinga.com/markets/cannabis/24/09/40900626/legal-medical-cannabis-could-save-us-healthcare-29b-annually-new-study-finds">Leafwell</a> aims to educate potential patients and partners, ensuring that therapeutic users are continually informed and supported, but Fisher recognized there&#8217;s much to be done still in that matter.
As regulations shift and new consumers enter the market, she said, "a lot of them are looking for therapeutic uses but don't get a medical card." Fisher attributes this to barriers that make navigating medical and adult-use markets challenging. To address those barriers, her company provides the largest integrated treatment clinic in the field, working across multiple markets where both programs coexist.
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/09/40900626/legal-medical-cannabis-could-save-us-healthcare-29b-annually-new-study-finds">Legal Medical Cannabis Could Save US Healthcare $29B Annually, New Study Finds</a>
<h3 class="wp-block-heading">The Importance Of Medical Integrity</h3>
Tim Pickett, CEO of Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>), a company based in Utah that offers plant-based treatments, echoed concerns about the potential risks to the medical cannabis sector. He explained that while retailers push for higher volumes, focusing on adult-use sales may come at a cost. "The fear is delegitimizing cannabis as a medicine.&#8221;
This shift risks overlooking a larger base of therapeutic cannabis users who might benefit from cannabis for health reasons but perceive it as purely recreational. Pickett advised that investors consider the long-term implications of focusing on adult-use marijuana, underscoring the substantial consumer base for medical cannabis.
<ul>
<li>Get Benzinga&#8217;s exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter&nbsp;<a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you&#8217;re serious about the business, you can&#8217;t afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Exploring Identity And Wellness</h3>
Ricky Williams, <a href="https://www.benzinga.com/topic/ricky-williams">former NFL player</a> and founder of Highsman, addressed the broader, often philosophical aspects of cannabis in health. Reflecting on his experience as a professional athlete, Williams highlighted how perspectives on health vary, especially in fields like sports. "My interaction with physicians is very different than for most people," making the point that every person has a particular relation to both health and physicians. Thus, he advocated for broader conversations on cannabis&#8217;s therapeutic uses, as many consumers are likely unaware of the plant's benefits beyond recreational purposes.
Building on that conversation Javier Hasse, managing director at Benzinga Cannabis, brought up a conceptual distinction that resonated with the panel: the difference between "medical cannabis" and "therapeutic cannabis," which encompasses a wider range of health benefits.
"Why would people choose to go through the adult-use market route when medical cannabis might be more affordable and accessible?" Hasse asked.
This question underscores a common barrier in the U.S. where concerns about medical marijuana registration impacting government benefits, like housing or employment rights, prevent many from fully engaging in the <a href="https://www.benzinga.com/markets/cannabis/24/10/41176039/whats-the-difference-between-medical-and-recreational-cannabis-users-new-survey-reveals-market-t">medical market</a>.
Confusion might be to blame, the panelists agreed noting that ambiguity and disorientation around cannabis legalization across states only exacerbate access challenges. 
"The fact that we are not scheduled properly, and all 50 states are doing their own things, makes it difficult for consumers to understand what registering for a card looks like for their jobs, housing, and community," said Betancourt Johnson.
The panel concluded that unified clarity from cannabis advocates and regulators would enhance patient rights, reduce confusion and ultimately bolster the wellness cannabis market, which still has much room to grow.
<ul>
<li>Read Next: <a href="https://www.benzinga.com/markets/cannabis/24/10/41545226/thc-potency-isnt-everything-here-are-some-strategies-to-deal-with-industry-challenges">THC Potency Isn&#8217;t Everything: Here Are Some Strategies To Deal With Industry Challenges</a></li>
</ul>

Health Care

Events

General

KDLY

Ricky Williams And Wellness Experts Discuss Strategies For Cannabis Patient-Centric Care

Senator Bernie Sanders (I-Vt.) has expressed strong criticism of Donald Trump&#8217;s proposal to eliminate all income taxes, describing it as &#8216;insane economics&#8217; that would disproportionately benefit the wealthy.
What Happened: On Wednesday, Sanders took to X to voice his disapproval of Trump&#8217;s tax plan. He argued that the proposal would harm the poorest members of society while further enriching the wealthiest individuals. Sanders also suggested that the plan&#8217;s popularity among billionaires was due to their potential financial gain.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Donald Trump&#39;s plan to eliminate all income taxes is insane economics. It will hurt desperately poor people and further enrich the very wealthy. That&#39;s why the billionaires who are pouring tens of millions of dollars into his campaign are so excited about it. <a href="https://t.co/pHX7yE7Puw">pic.twitter.com/pHX7yE7Puw</a>
&mdash; Bernie Sanders (@BernieSanders) <a href="https://twitter.com/BernieSanders/status/1851760120478171153?ref_src=twsrc%5Etfw">October 30, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Sanders shared a video of him appearing on NBC News in the post in which he said protecting American democracy and protecting a woman&#8217;s right to control her own body were enormously important to him. He pointed out that Trump thought climate change was a hoax is also of &#8220;enormous importance.&#8221;
Sanders said over the last 50 years there has been a &#8220;massive transfer of wealth from the bottom 90% to the top 1%.&#8221; He said &#8220;60% of our people are living paycheck-to-paycheck while the billionaire class has never had it so good, while Donald Trump wants to give even more tax breaks to billionaires.&#8221;
&#8220;This would be the biggest transfer of wealth in the history of this country. It would mean the billionaire class, the millionaires, no longer pay a nickel in taxes.&#8221;
He contrasted it by saying that under Trump&#8217;s proposals if someone went to the grocery store or if they went to buy a refrigerator and if you&#8217;re a working-class person the prices are going to soar.
&#8220;The idea that you eliminate all taxes and replace them by a tariff is insane economics,&#8221; said Sanders.
His post comes in the context of the upcoming 2024 U.S. presidential election, where both Trump and Vice President Kamala Harris have proposed <a href="https://www.benzinga.com/government/24/10/41611073/trump-vs-harris-how-their-fiscal-plans-could-add-trillions-to-the-us-national-debt">expansive tax and spending measures</a> that could significantly increase the national debt, according to a recent analysis by the Committee for a Responsible Federal Budget (CRFB).
See Also: <a href="https://www.benzinga.com/news/24/10/41590597/bernie-sanders-explains-why-he-will-vote-for-kamala-harris-even-though-he-disagrees-with-her-stance?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Bernie Sanders Explains Why He Will Vote For Kamala Harris Even Though He Disagrees With Her Stance On Israel</a>
Why It Matters: Sanders&#8217; criticism of Trump&#8217;s tax plan aligns with his previous comments on the former president&#8217;s policies. In an interview with Politico, Sanders <a href="https://www.benzinga.com/news/24/08/40453368/bernie-sanders-trump-labeled-kamala-harris-an-extreme-communist-on-her-price-gauging-plan-but-doesnt">dismissed Trump&#8217;s claims</a> that Harris&#8217; price-gouging proposal was equivalent to price controls and labeled her as an &#8220;extreme communist&#8221;.
Furthermore, Sanders has previously expressed his views on the need for better healthcare, expanded Social Security, and a higher minimum wage. He has accused Trump of prioritizing <a href="https://www.benzinga.com/general/politics/24/08/40448543/bernie-sanders-trump-just-wants-to-give-billionaires-another-tax-break-this-november-the-choice-">tax breaks for billionaires</a> over these issues.
The 2024 presidential election is expected to be a close race between Trump and Harris, with prediction markets <a href="https://www.benzinga.com/general/sports-betting/24/10/41589659/trump-vs-harris-state-by-state-2024-election-betting-odds-which-candidate-is-favored-to-wi">currently favoring Trump.</a>
Image via Flickr
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Politics

Bernie Sanders Says Trump's Plan To Eliminate All Income Taxes Is Insane Economics: Will Trigger The 'Biggest Transfer Of Wealth In The History Of This Country'

Former President Donald Trump used a campaign-themed garbage truck to highlight a controversial remark by President Joe Biden, which appeared to label Trump supporters as &#8220;garbage&#8221;.
What Happened: Trump rode in a garbage truck decorated with his campaign sticker and flag during his motorcade in Wisconsin on Wednesday. &#8220;How do you like my garbage truck? This truck is in honor of Kamala and Joe Biden,&#8221; Trump said from the passenger seat, <a href="https://thehill.com/homenews/campaign/4962923-trump-rides-garbage-truck-to-seize-biden-comment/">reported</a> The Hill.
The Trump campaign has been leveraging the anger among supporters over Biden&#8217;s comment, even though Vice President Harris has distanced herself from the statement. &#8220;First of all, he clarified his comments but let me be clear: I strongly disagree with any criticism of people based on who they vote for,&#8221; Harris told reporters.
Biden&#8217;s comment, which ignited a backlash, was made while addressing on a racist joke by a comedian at a Trump rally. The White House issued a statement arguing that Biden was referring to the rhetoric at the rally as &#8220;garbage&#8221;, not the supporters. The statement included a transcript of the comment, indicating Biden was referring to the comedian&#8217;s &#8220;demonization of Latinos&#8221; as &#8220;garbage&#8221;.
A video clip of Biden&#8217;s remarks quickly went viral, with many Republicans comparing the remarks to Hillary Clinton&#8217;s 2016 comments about some of Trump&#8217;s supporters being &#8220;deplorable.&#8221;
See Also: <a href="https://www.benzinga.com/news/24/10/41564409/michelle-obama-criticizes-trump-at-michigan-harris-rally-why-on-earth-is-this-race-even-close?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Michelle Obama Criticizes Trump At Michigan Harris Rally: &#8216;Why On Earth Is This Race Even Close?&#8217;</a>
Why It Matters: The controversy stems from a <a href="https://www.benzinga.com/news/24/10/41565160/puerto-rico-called-a-floating-island-of-garbage-in-the-middle-of-the-ocean-at-trump-rally-comments-a">Trump rally</a> where comedian Tony Hinchcliffe made derogatory comments about Puerto Rico and Latinos. These remarks sparked immediate criticism from Democrats and the Harris campaign. 
The fallout from the &#8220;floating island of garbage&#8221; comment led to <a href="https://www.benzinga.com/news/24/10/41615257/floating-island-of-garbage-fallout-kamala-harris-recieves-endorsement-from-puerto-ricos-largest-news">Kamala Harris receiving an endorsement</a> from Puerto Rico&#8217;s largest newspaper, El Nuevo Día, amidst the controversy.
Image via Flickr
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

Trump Rides Garbage Trump In Efforts To Amplify Biden's 'Garbage' Comment

STBX

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

Billionaire Elon Musk previously sold all his homes so he could live a more minimalistic life, moving to Texas to be closer to his many <a href="https://www.benzinga.com/news/24/07/39804744/spacex-x-to-move-headquarters-from-california-to-texas-musk-calls-it-the-final-straw-criticizes-gov">business operations there.</a>
Musk is now looking to build a secret compound for his kids and their mothers, according to a new report.
What Happened: Musk has <a href="https://www.benzinga.com/general/education/24/06/39547388/happy-birthday-elon-musk-53-facts-and-figures-about-tesla-spacex-ceo-on-his-53rd-birthday">fathered 12 children</a> with three different women and his new plans could be to have his children live close to each other to maximize his time with them as he remains a busy man running several companies.
Musk has bought several properties near each other in the Austin, Texas, area, according to a <a href="https://www.nytimes.com/2024/10/29/business/elon-musk-children-compound.html?partner=slack&amp;smid=sl-share">report </a>from the New York Times.
Included in the properties is a 14,400-square-foot home that could be the centerpiece of a planned family compound. Behind the larger property is a smaller six-bedroom mansion.
Musk spent $35 million for the two properties according to the report. The billionaire stays at a third mansion, which he can reach in a short 10-minute walk.
Shivon Zilis, who is an executive at Musk's Neuralink, moved into one of the houses with her children, according to the report. Musk and Zilis have three children together, twins Strider and Azure born in November 2021, and a child born in 2024, whose name has not been revealed.
While one mother of some of Musk's kids is supportive of the idea, another hasn't been supportive. Claire Boucher, better known as musician Grimes, is in a legal fight with Musk currently. Musk and Grimes have three children together.
Musk's first wife Justine Musk is the other mother of his children and the report did not say if she was receptive to the idea of a family compound. Musk and his first wife had six children together, with five living and one having previously passed away at the age of 10 months.
One of the five living children with his first wife is transgender and changed her legal name, distancing herself from her father.
Operations for Tesla, SpaceX and X can all be found in Texas, where Musk now spends a good portion of his time.
You may not be a billionaire like Elon Musk, but you can uncover hidden gems in the stock market using our proprietary data and pattern recognition — <a href="https://www.benzinga.com/general/entertainment/24/10/41187322/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">check out five </a><a href="https://www.benzinga.com/real-estate/reit/24/10/41549488/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">stocks </a><a href="https://www.benzinga.com/general/entertainment/24/10/41187322/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">flying under the radar that deserve your attention.</a>
Why It's Important: Musk's real estate purchases come as he has for years talked <a href="https://www.benzinga.com/news/24/06/39443823/elon-musk-once-said-collapsing-birth-rate-is-the-biggest-danger-civilization-faces-he-has-fathered-1">about declining birthrates</a> and encouraged people to have as many children as possible to save humankind.
"It should be considered a national emergency to have kids," Musk said previously in June 2024.
Musk is supportive of in-vitro fertilization (IVF), which was used for several of his children. The billionaire has also volunteered donating sperm to at least one person to father more children, according to the report.
The real estate dealings of Musk have drawn increased interest from the press and the <a href="https://www.benzinga.com/news/23/09/34743808/elon-musk-glass-house-case-sees-justice-department-looking-into-personal-benefits-from-tesla-the-lat">U.S. Department of Justice (DOJ) previously.</a>
Musk was reported <a href="https://www.benzinga.com/news/23/07/33200386/did-elon-musk-have-a-secret-glass-house-project-in-texas-new-report-looks-into-project-42">building a secret glass house</a> several years ago, which he denied. The DOJ launched an investigation into whether the house was using resources from Tesla.
Around the same time of the investigation, Musk was said to begin touring Austin looking for homes and later lived in a 6,900-square-foot house in the area with Boucher. The billionaire got the idea of buying more property near that home to start the family compound.
Musk is currently the richest person in the world worth an estimated $270 billion by <a href="https://www.bloomberg.com/billionaires/?sref=TBDibEcD">Bloomberg</a>.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/23/02/30928396/elon-musk-the-landlord-tesla-ceo-might-be-bringing-houses-to-employees-with-this-company">Elon Musk, The Landlord? Tesla CEO Might Be Bringing Houses To Employees With This Company</a></li>
</ul>
Photo: Elon Musk and Grimes (Claire Boucher), Photo by Sky Cinema on Shutterstock

Entertainment

Elon Musk Want His 11 Kids, Their Mothers To Live In Secret Compound He Bought, New Report Says

Buenaventura Mining Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BVN#NYSE">BVN</a>) reported quarterly earnings of $0.93 per share. The company reported quarterly sales of $331.100 million which beat the analyst consensus estimate of $263.025 million by 25.88 percent. This is a 56.70 percent increase over sales of $211.300 million the same period last year.

Earnings

Earnings Beats

Buenaventura Mining Co Q3 2024 GAAP EPS $0.93, Sales $331.100M Beat $263.025M Estimate

Editor&#8217;s Note: The fourth-quarter revenue estimate was corrected. 
Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) reported third-quarter financial results after the market close on Wednesday. Here&#8217;s everything <a href="https://www.benzinga.com/pressreleases/24/10/n41635757/meta-reports-third-quarter-2024-results">you need to know from the quarter</a>.
Q3 Earnings: Meta reported third-quarter revenue of $40.59 billion, beating&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">analyst estimates</a>&nbsp;of $40.29 billion. The company reported third-quarter adjusted earnings of $6.03 per share, beating analyst estimates of $5.25 per share.
Meta has now beat analyst estimates on the top and bottom lines in seven consecutive quarters, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Total revenue was up 19% on a year-over-year basis. Family daily active people were up 5% year-over-year to 3.29 billion. Ad impressions jumped 7% year-over-year and average price per ad increased by 11% year-over-year.
Costs and expenses came in at $23.24 billion, up 14% year-over-year. Capital expenditures came in at $9.2 billion. The company ended the quarter with $70.9 billion in cash, cash equivalents and marketable securities, and $28.82 billion of long-term debt.
Meta noted that its headcount was up 9% year-over-year to 72,404 as of Sept. 30.
&#8220;We had a good quarter driven by AI progress across our apps and business,&#8221; said&nbsp;Mark Zuckerberg, founder and CEO of Meta. &#8220;We also have strong momentum with Meta AI, Llama adoption, and AI-powered glasses.&#8221;
Related Link: <a href="https://www.benzinga.com/markets/equities/24/10/41629264/alphabets-earnings-rally-pushes-magnificent-7-market-cap-to-record-16-8-trillion-10-tech-heavy-e">Alphabet&#8217;s Earnings Rally Pushes Magnificent 7 Market Cap To Record $16.8 Trillion: 10 Tech-Heavy ETFs Moving Wednesday</a>
Outlook: Meta expects fourth-quarter revenue to be in the range of $45 billion to $48 billion versus an estimate of $46.31 billion. 
Meta expects full-year 2024 total expenses to be in the range of&nbsp;$96 billion to $98 billion, versus prior guidance of $96 to $99 billion. The company expects full-year 2024 capital expenditures to be in the range of&nbsp;$38 billion to $40 billion, versus its prior guidance range of&nbsp;$37 billion to $40 billion.
&#8220;For Reality Labs, we continue to expect 2024 operating losses to increase meaningfully year-over-year due to our ongoing product development efforts and investments to further scale our ecosystem,&#8221; the company said. 
Meta executives will hold a conference call to discuss the company&#8217;s quarterly results at 5 p.m. ET.
META Price Action:&nbsp;<a href="http://benzinga.com/quote/meta">Meta Platforms shares</a> were up approximately 68% year-to-date heading into the report. The stock was flat after-hours, trading at $592 at the time of publication Wednesday, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41633790/apple-refreshes-macbook-pro-lineup-with-m4-pro-and-m4-max-3nm-chips">Apple Refreshes MacBook Pro Lineup With M4 Pro and M4 Max 3Nm Chips</a></li>
</ul>
Photo: Shutterstock.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: Meta Platforms Q3 2024 Earnings Call &#x7C; $META" width="500" height="281" src="https://www.youtube.com/embed/MhZMnqaYVMM?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>

After-Hours Center

Meta Platforms Q3 Earnings: Revenue Beat, EPS Beat, Daily Actives Up 5%, 'Strong Momentum' In AI (CORRECTED)

Hamilton Beach Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBB#NYSE">HBB</a>) .

Guidance

Hamilton Beach Brands expects FY 2024 Cash Flow from operating activities less cash used for investing activities to be at the high end of $25M to $35M per year.

CORRECTION: Meta Platforms Sees Q4 Revenue $45B-$48B Vs $46.31B Est.

Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) sees Q4 sales of $333.000 million-338.000 million vs $329.28 million estimate.

TRUP

Trupanion Sees Q4 Sales $333.000M-338.000M vs $329.28M Est.

Trupanion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) raises FY2024 sales outlook from $1.26 billion-1.28 billion to $1.28 billion-1.29 billion.

Trupanion Raises FY2024 Sales Guidance from $1.26B-1.28B to $1.28B-1.29B.

The Company announced the appointment of Mr. Konstantinos Ferderigos as General Manager for its Greek Operations.&nbsp;
&nbsp;

Advent Technologies Reveals Changes To Its Board And C-suite By Removing Chairman And CEO Vasilis Gregoriou And Chief Strategy Officer Chris Kaskavelis

Silicon Motion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) sees Q4 sales of $191.000 million-202.000 million vs $208.21 million estimate.

SIMO

Silicon Motion Technology Sees Q4 Sales $191.000M-202.000M vs $208.21M Est

The market has been high on Anixa Biosciences Inc (ANIX)  stock recently. ANIX gets a Bullish score from InvestorsObserver Stock Sentiment Indicator. Anixa Biosciences Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on ANIX!See Full ANIX ReportWhat is Stock Sentiment?W

Should You Buy Anixa Biosciences Inc (ANIX) Stock on Wednesday?

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report) today and set a price target of $12.00. Yi Ch...

Anixa Biosciences: A Buy Rating on Strong Financials and Promising Oncology Advances

Anixa Biosciences Inc (ANIX) has provided an announcement. Anixa Biosciences, Inc. successfully held its 2024 annual meeting, where stockholders re...

Anixa Biosciences Stockholders Affirm Confidence and Oversight

Anixa Biosciences enters JV with Cleveland Clinic for additional cancer vaccines

Anixa Biosciences Inc (ANIX) has shared an update. Anixa Biosciences, Inc. has partnered with the Cleveland Clinic Foundation to develop cancer vac...

Anixa Biosciences Forms Cancer Vaccine Partnership with Cleveland Clinic

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks.</a> Developing therapeutics to cure diseases is a complex business model fraught with the potential to fail at many points.&nbsp;



Developmental and regulatory time frames are long, introducing multiple potential points of failure. The capital necessary for research and development is substantial. So on and so forth. The result is that many&nbsp;upstart biotech firms fail to commercialize, taking their equity down in the process.



Those firms that make it through and reach commercialization are rewarded with the spoils of success. They pay shareholders handsomely with returns that can turn a small investment into a fortune. The firms discussed below still have reasonable chances of commercialization and the potential to reward investors handsomely. Even if they don&rsquo;t ultimately reach success, they can still reward investors handsomely as they pass milestones in the development process.



<h2>FibroGen (FGEN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div>FibroGen (NASDAQ:<a href="https://investorplace.com/stock-quotes/fgen-stock-quote/">FGEN</a>) continues on the path toward commercialization for multiple drugs, targeting multiple diseases. The firm&rsquo;s leading candidate drugs include Pamrevlumab, Roxadustat and several other oncology therapeutics.



Pamrevlumab is currently in Phase 3 clinical trials for the treatment of a certain form of pancreatic cancer. It is also concurrently being studied in phase 2/3&nbsp;clinical studies for metastatic pancreatic cancer. Roxadustat is a drug that induces the production of red blood cells and is approved in multiple countries for use in treating anemia in chronic kidney disease populations. A supplemental New Drug Application (sNDA) has been submitted in China for the drug. It has been accepted for review by the China Health Authority.&nbsp;



One of the more compelling aspects of FibroGen as an investment in financial performance. During the <a href="https://www.globenewswire.com/news-release/2024/05/06/2876129/33525/en/FibroGen-Reports-First-Quarter-2024-Financial-Results.html">first quarter, revenues</a> approached $56 million, up from $36 million a year earlier. The increased revenues allow the company to slash its net losses from $76.7 million to just below $32 million this quarter. Shares currently trade for $1.30 with a <a href="https://stockanalysis.com/stocks/fgen/forecast/">consensus target price of $5</a> and analyst targets ranging as high as $11.



<h2>Nuvectis Pharma (NVCT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div>Nuvectis Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvct-stock-quote/">NVCT</a>) is another oncology-oriented biotech stock. It&rsquo;s particularly interesting as a potential investment because while it is in the pre-revenue stages, it is also highly regarded and priced higher than one might expect.



Shares currently trade for $6.21, which is quite high for a pre-revenue biotech firm. Those shares have coverage from a single analyst who expects their value to rise to $22 in the future. Investors who look at the company&rsquo;s financial statements will see that it is basically treading water. NVCT has more than $19 million in liquidity and loses roughly $4 million a quarter on R&amp;D and administrative costs.&nbsp;



The reason for optimism surrounding Nuvectis Pharma is simple: Lead candidate drug <a href="https://www.globenewswire.com/news-release/2024/05/07/2876700/0/en/Nuvectis-Pharma-Inc-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html">NXP800 has been granted</a> fast-track designation by the FDA in platinum-resistant ARID1a-mutated ovarian cancer. It&rsquo;s currently in Phase 1b studies and has the potential to pass through multiple milestones moving forward that, if successful, will reward investors with strong and immediate returns.



<h2>Relmada Therapeutics (RLMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div>Relmada Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/rlmd-stock-quote/">RLMD</a>) is one of many promising late-stage biotech firms developing therapeutics to address diseases of the central nervous system. Those diseases include disorders with high unmet needs including major depressive disorder (MDD), a primary focus of the firm.



REL-1017 is one of the company&rsquo;s lead candidate drugs. The drug is in late-stage development for the treatment of MDD. It is being studied to understand the potential of the drug as a fast-acting, once-daily antidepressant treatment.&nbsp;It is currently being studied in two Phase 3 double placebo-controlled studies.



The company also acquired the rights to a psilocybin and derivatives program&nbsp;in 2021. That program has been rebranded as REL-P11 and is being studied for its efficacy in both neurogenesis and in ameliorating the effects of neurodegenerative conditions.&nbsp;



Psilocybin and other psychoactive drugs are currently a hot area of research. Although Ralmada Therapeutics is in the pre-revenue stages and shares trade for $3.04, the sole analyst with coverage believes those shares could be worth as much as $25 in the future.



<h2>Anixa Biosciences (ANIX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-1-300x169.jpg" alt="A scientist holds a test tube while it is in a container"><div>Source: Shutterstock</div></div>Anixa Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/anix-stock-quote/">ANIX</a>) develops treatments and vaccines to address unmet needs in ovarian cancer and breast cancer. Shares currently trade for less than $3, while the single analyst with coverage believes the stock will <a href="https://www.pricetargets.com/NASDAQ/ANIX/">rise to $12 in value.</a>&nbsp;



The company very <a href="https://www.prnewswire.com/news-releases/anixa-biosciences-commences-treatment-of-fifth-patient-in-ovarian-cancer-car-t-clinical-trial-302150758.html">recently commenced treatment</a> on the 5th patient in an ovarian cancer CAR-T clinical trial. The company is enrolling patients in its first-in-human trial who were unresponsive to at least two prior therapies. Safety was confirmed in the first three-patient cohort. The company is tripling the dose in patients four and five in order to establish dosage tolerability.&nbsp;



The company also recently expanded its partnership with the Cleveland Clinic to develop cancer vaccines. That partnership aims to further the development of vaccines targeting rare and aggressive forms of breast and ovarian cancer. Anixa Biosciences will continue to be an interesting stock for investors, especially in light of strong positive news on multiple fronts.



<h2>Genenta Science (GNTA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div>Let&rsquo;s begin discussing Genenta Science (NASDAQ:<a href="https://investorplace.com/stock-quotes/gnta-stock-quote/">GNTA</a>) stock in relation to its safety as an investment overall. Readers have noticed that multiple recommendations above have only one analyst rating. I don&rsquo;t have to explain why that introduces a lot of risk overall. The thing I want to note about Genenta Science is that it has <a href="https://stockanalysis.com/stocks/gnta/forecast/">two target prices,</a> one at $15 and the other at $25. Thus, the consensus price is $20. Genenta Science shares trade at $3.30.



While the company is attractive for its raw return potential, I should also note that there are a lot of unknowns with this company. It is an Italian company and doesn&rsquo;t provide a lot in the way of information. It&rsquo;s a lot easier to find updates on domestic companies. The information we do have is a<a href="https://ir.genenta.com/static-files/db77523d-9bdf-47bd-8120-02eb11e0d7df"> financial report dating from the end of 2023.</a> It simply shows the company is not producing much in the way of revenues.



The stock offers so much potential because the company is developing a stem cell platform for the safe treatment of solid tumors. It has <a href="https://www.globenewswire.com/news-release/2024/02/08/2825783/0/en/Genenta-Demonstrated-Reprogramming-of-the-Tumor-Microenvironment-in-GBM-Patients-Paving-the-Way-for-Innovative-Treatments-of-Solid-Tumors.html">demonstrated the potential</a> to reprogram the cells of glioblastoma patients.&nbsp;



<h2>Affimed (AFMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/red-blood-cells-300x169.jpg" alt="3d rendering red blood cells in vein"><div>Source: Phonlamai Photo / Shutterstock.com</div></div>Affimed (NASDAQ:<a href="https://investorplace.com/stock-quotes/afmd-stock-quote/">AFMD</a>) continues to develop therapeutics for the treatment of lymphoma, a grouping of blood cancers that originate in the lymphatic system.



The stock is interesting for a number of reasons both operational and developmental. The company reduced <a href="https://www.globenewswire.com/news-release/2024/03/28/2853795/0/en/Affimed-Reports-2023-Financial-Results-and-Operational-Progress.html">its workforce by 50% in 2023</a> in an effort to streamline operations.



AFMD is redirecting its resources to three lead candidate programs following the restructuring. That leads me to my next point: The company is doing well from a developmental perspective. Each of those three candidate programs progressed in 2023. Affimed awaits further data readouts from those programs in Q2 and expects dose escalation. That implies current safety and will be used to establish the upper tolerability for those respective programs.&nbsp;



As with any penny biotech stock, failure is a distinct possibility. However, Affimed is well regarded and benefits from a <a href="https://stockanalysis.com/stocks/afmd/forecast/">consensus target price of $32.</a> It currently trades for just over $4.&nbsp;



<h2>Lipocine (LPCN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div>Lipocine (NASDAQ:<a href="https://investorplace.com/stock-quotes/lpcn-stock-quote/">LPCN</a>) stock trades for $6.89 but is expected to rise to $33. Like so many other stocks on this list, Lipocine only has coverage from one analyst. That introduces risk to what is already a risky biotech stock. However, that&rsquo;s the game investors must be willing to play in the risk-fueled world of pharma stock&nbsp;investing.



As you may have guessed by the firm&rsquo;s name, Lipocine does work in the obesity management space. Candidate drug Lpcn2401 is currently in Phase 2 studies and is showing promise in reducing obesity in patients with at least one co-related morbidity.



However, the company is also developing treatments outside of the weight loss realm. Those programs span disease areas, including postpartum depression, cirrhosis, essential tremors and testosterone replacement therapy.&nbsp;



What&rsquo;s particularly good about the company is that it actually produced positive net income in the most recent quarter. Lipocine <a href="https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2024-302140431.html">reported $3.5 million in net income</a> in the first quarter, reversing a $3.9 million net loss 12 months prior.



On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.



Read More: <a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a>



On the date of publication, Alex Sirois did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"> Publishing Guidelines.</a>
<div>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/7-penny-biotech-stocks-to-triple-your-investment/">7 Penny Biotech Stocks to Triple Your Investment</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

7 Penny Biotech Stocks to Triple Your Investment

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Anixa Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/anix-stock-quote/">ANIX</a>) just reported results for the second quarter of 2024.<ul><li>Anixa Biosciences reported earnings per share of -10 cents. This was above the analyst estimate for EPS of -11 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/anix-stock-earnings-anixa-biosciences-for-q2-of-2024/">ANIX Stock Earnings: Anixa Biosciences Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ANIX Stock Earnings: Anixa Biosciences Beats EPS for Q2 2024

Anixa Biosciences authorizes $5M share buyback program

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report) and keeping the price target at $7.00. Y...

Buy Rating Affirmed for Anixa Biosciences Amid Promising Cancer Therapy Trials

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report), retaining the price target of $7.00. Yi C...

Buy Rating Affirmed for Anixa Biosciences Amid Promising CAR-T Therapy Trials and Stable Financials

AFMD

ANIX

FGEN

GNTA

LPCN

NVCT

RLMD

Press Releases

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Clinical Trial at the International Gynecologic Cancer Society 2024 Annual Meeting

Anixa Biosciences (NASDAQ:ANIX) Gains Attention for Its Innovative Cancer Therapies Amid Biopharma Sector Growth

Anixa Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Rivkin Center-AACR 15th Biennial Ovarian Cancer Research Symposium

Anixa Biosciences Announces Presentation on its Ovarian Cancer CAR-T Therapy at the Ovarian Cancer Research Alliance's International Gynecologic Cancer Conference

Anixa Biosciences Unveils Phase 2 Study Plan for Breast Cancer Vaccine

Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial

Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Comments

Anixa Biosciences

Anixa Biosciences (ANIX) Opciones

Anixa Biosciences (NASDAQ:ANIX) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL